August 14, 2026

Ascendis -2.4% Friday + BioMarin ITC Pending, Amylyx LUCIDITY Readout Imminent, Kailera $42.60 Analyst PT, Frog AMP Paper

Ascendis -2.4% Friday despite EPS beat, BioMarin ITC opinion pending. Amylyx LUCIDITY late Aug. Kailera $42.60 PT. Frog AMP review paper.

4 stories · Covering industry, clinical-trials, research

Editor's Note

Friday's peptide news is anchored by earnings-week follow-through and clinical readout windows across three peptide categories: rare-disease franchise economics, next-gen obesity pipelines, and non-GLP-1 mechanism trials. Ascendis Pharma (NASDAQ: ASND) shares fell approximately 2.4% Friday premarket to $249.28 despite reporting Q2 2026 EPS of $2.83 (beating $1.51 consensus by 87%) on revenue of $339.3 million (beating $326.5 million consensus) with product revenue of €315 million (+105% year-over-year) led by YORVIPATH at €252 million; the market response reflects investors balancing the beat against the ongoing International Trade Commission (ITC) patent-infringement case brought by BioMarin (NASDAQ: BMRN) over the YUVIWEL (TransCon CNP for achondroplasia) launch that directly competes with BioMarin's Voxzogo (vosoritide). BioMarin owns U.S. Patent No. RE48,267 covering the peptide analog variants, and a first ITC opinion is expected in August 2026 following the March 2026 Federal Circuit ruling against Ascendis on the mandatory-stay question. Amylyx Pharmaceuticals (NASDAQ: AMLX) is on track for the registrational Phase 3 LUCIDITY trial top-line data readout in late August or early September 2026, having completed the final study visit in the 16-week double-blind period of the trial that enrolled 78 patients across 21 US sites and randomized them 3:2 to avexitide 90 mg subcutaneous once daily or placebo; if positive, commercial launch of avexitide (exendin 9-39, a GLP-1 receptor antagonist peptide) for post-bariatric hypoglycemia is anticipated in 2027. Kailera Therapeutics (NASDAQ: KLRA) received sweeping positive analyst coverage following its August 12 Q2 report, with 6 analysts averaging a Strong Buy rating and $42.60 12-month price target (representing 82.83% upside from the $17.95-$19.50 Aug 13-14 trading range), including TD Cowen at Buy with a $57 price target. And in non-GLP-1 research, MDPI Antibiotics published a review synthesizing the dual antimicrobial-and-anticancer activity of frog-skin-derived peptides including dermaseptins, temporins, and brevinins, adding to the growing evidence map on antimicrobial peptide (AMP) therapeutic potential in oncology.

Industry

Ascendis Pharma (NASDAQ: ASND) Shares Fell Approximately 2.4% Premarket Friday August 14 to $249.28 (Compared to Thursday Close of $255.46) Despite Reporting Q2 2026 EPS of $2.83 (Beating the $1.51 Analyst Consensus by 87%) on Revenue of $339.3 Million (Beating the $326.5 Million Consensus) With Product Revenue of €315 Million (+105% Year-Over-Year) Led by YORVIPATH at €252 Million; The Market Response Reflects Investors Balancing the Substantive Beat Against the Ongoing International Trade Commission (ITC) Patent-Infringement Case Brought by BioMarin Pharmaceutical (NASDAQ: BMRN) Over the YUVIWEL (TransCon CNP for Achondroplasia) Launch That Directly Competes With BioMarin's Voxzogo (Vosoritide); BioMarin Owns U.S. Patent No. RE48,267 Covering the Peptide Analog Variants, and a First ITC Opinion Is Expected in August 2026 Following the March 26, 2026 Federal Circuit Ruling Against Ascendis on the Mandatory-Stay Question in Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc.

Ascendis Pharma (NASDAQ: ASND) shares fell approximately 2.4% premarket Friday August 14, 2026 to $249.28 (compared to Thursday close of $255.46) despite reporting Q2 2026 EPS of $2.83 (beating the $1.51 analyst consensus by 87%) on revenue of $339.3 million (beating the $326.5 million consensus). Q2 2026 product revenue reached €315 million (+105% year-over-year) led by YORVIPATH (palopegteriparatide) at €252 million, SKYTROFA (lonapegsomatropin) at €55 million, and YUVIWEL (TransCon CNP for achondroplasia) at €8 million in its first US quarter with 220+ patient enrollments through July 31. The company ended Q2 2026 with €812 million in cash, no bank or convertible debt, and expects to generate more than €500 million in operating cash flow this year. The market response reflects investors balancing the substantive beat against the ongoing International Trade Commission (ITC) patent-infringement case brought by BioMarin Pharmaceutical (NASDAQ: BMRN) over the YUVIWEL launch. BioMarin owns U.S. Patent No. RE48,267 covering peptide analog variants including its FDA-approved Voxzogo (vosoritide). A first ITC opinion is expected in August 2026 following the March 26, 2026 Federal Circuit ruling in Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc. that a party cannot use voluntary dismissal to restart a statutory deadline it already missed. The case represents the first substantive peptide-vs-peptide patent battle in the achondroplasia commercial category.

#ascendis-pharma #asnd #biomarin #bmrn #yuviwel #voxzogo #transcon-cnp #achondroplasia #itc-patent-lawsuit #us-patent-re48267 #federal-circuit #peptide-patent-battle #q2-2026-aftermath

Clinical Trials

Amylyx Pharmaceuticals (NASDAQ: AMLX) Is on Track for the Registrational Phase 3 LUCIDITY Trial Top-Line Data Readout in Late August or Early September 2026, Having Completed the Final Study Visit in the 16-Week Double-Blind Period of the Trial That Enrolled 78 Patients With Post-Bariatric Hypoglycemia (PBH) Across 21 US Sites and Randomized Them 3:2 to Avexitide 90 mg Subcutaneous Once Daily or Placebo; The FDA-Agreed-Upon Primary Endpoint Is Reduction in the Composite of Level 2 and Level 3 Hypoglycemic Events Through Week 16; The Trial Design Was Informed by Data From Five Prior Clinical Trials of Avexitide in PBH That Consistently Showed Statistically Significant Reductions in Level 2 and Level 3 Hypoglycemic Events; If Positive, Commercial Launch of Avexitide (Exendin 9-39, a Peptide GLP-1 Receptor Antagonist) Is Anticipated in 2027 for the Indication With No Currently Approved Drug Therapy

Amylyx Pharmaceuticals (NASDAQ: AMLX) is on track for the registrational Phase 3 LUCIDITY trial top-line data readout in late August or early September 2026. Trial status: the last participant completed the final study visit in the 16-week double-blind period. Trial design: 78 patients with post-bariatric hypoglycemia (PBH) enrolled across 21 US sites and randomized 3:2 to avexitide 90 mg subcutaneous once daily or placebo for 16 weeks. Primary endpoint (agreed with the FDA): reduction in the composite of Level 2 (blood glucose < 54 mg/dL) and Level 3 (severe cognitive impairment requiring external assistance) hypoglycemic events through Week 16. The trial design was informed by data from five prior clinical trials of avexitide in post-bariatric hypoglycemia that consistently showed statistically significant reductions in Level 2 and Level 3 hypoglycemic events. Avexitide is exendin (9-39), a peptide GLP-1 receptor antagonist that binds the GLP-1 receptor without activating it, blocking excessive endogenous GLP-1 signaling that drives postprandial hypoglycemia in patients following Roux-en-Y gastric bypass surgery. If positive, commercial launch of avexitide is anticipated in 2027 for the indication that has no currently approved drug therapy. LUCIDITY is one of the most-watched near-term peptide-specific clinical catalysts and one of very few Phase 3 programs targeting a GLP-1 receptor antagonist rather than agonist mechanism.

#amylyx-pharmaceuticals #amlx #avexitide #exendin-9-39 #glp-1-receptor-antagonist #post-bariatric-hypoglycemia #lucidity #phase-3 #readout-imminent #roux-en-y-gastric-bypass #first-in-class #78-patients

Industry

Kailera Therapeutics (NASDAQ: KLRA) Received Sweeping Positive Analyst Coverage Following Its August 12 Q2 2026 Earnings Report Confirming an Active Investigational New Drug (IND) Application With the FDA for Ribupatide Oral (KAI-9531-T) and Global Phase 3 Obesity Trials Planned for H1 2027, With 6 Analysts Averaging a Strong Buy Rating and a $42.60 12-Month Price Target (Representing 82.83% Upside From the $17.95-$19.50 Trading Range on August 13-14), Including TD Cowen at Buy With a $57 Price Target, Evercore ISI at Outperform, and William Blair at Outperform; The Company Holds Cash, Cash Equivalents, and Marketable Securities Expected to Support Execution of Multiple Clinical Milestones With Runway Into Mid-2028; Ribupatide Is a Once-Weekly GLP-1/GIP Dual Agonist Peptide That Reached 23.6% Mean Weight Loss at 8 mg Over 36 Weeks in Phase 2 Injection Trial, With the Oral Formulation Reaching Up to 12.1% Weight Loss and 38.6% of Participants Achieving ≥15% Loss in Hengrui's Phase 2 Trial

Kailera Therapeutics (NASDAQ: KLRA) received sweeping positive analyst coverage following its August 12, 2026 Q2 2026 earnings report. Kailera confirmed an active Investigational New Drug (IND) application with the FDA for ribupatide oral (KAI-9531-T) and global Phase 3 obesity trials planned for H1 2027. Analyst response: according to 6 analysts, the average rating for KLRA stock is Strong Buy, with a 12-month average price target of $42.60 representing 82.83% upside from the $17.95-$19.50 trading range on August 13-14. Named ratings include TD Cowen at Buy with a $57 price target, Evercore ISI at Outperform, and William Blair at Outperform. The company holds cash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028. Ribupatide mechanism: a once-weekly GLP-1/GIP dual agonist peptide (mechanistically similar to Eli Lilly's tirzepatide) with the ribupatide injection Phase 2 trial reaching 23.6% mean weight loss at 8 mg over 36 weeks, and the oral formulation reaching up to 12.1% weight loss with 38.6% of participants achieving at least 15% loss at Week 26 in Hengrui's Phase 2 trial. The Phase 2b high-dose injection trial in obesity is fully enrolled with data anticipated in mid-2027.

#kailera-therapeutics #klra #ribupatide #analyst-coverage #strong-buy-rating #42-60-price-target #td-cowen #evercore-isi #william-blair #82-83-upside #glp-1-gip-dual-agonist

Research

MDPI Antibiotics Published a Review Paper Synthesizing the Dual Antimicrobial-and-Anticancer Activity of Frog-Skin-Derived Peptides Including Dermaseptins, Temporins, and Brevinins, Documenting Their Selective Membrane-Disruption Mechanism Against Both Bacterial Pathogens (Broad-Spectrum Cationic Amphipathic Activity Against Multidrug-Resistant Bacteria) and Cancer Cells (Selective Electrostatic Interactions With Negatively Charged Malignant Cell Membranes Producing Membrane Disruption Plus Apoptosis or Necrosis Induction); The Frog-Skin AMP Family Represents One of the Most-Studied Natural Sources of Bioactive Antimicrobial Peptides With Cross-Category Therapeutic Potential Extending the Broader Anticancer AMP Research Trajectory Anchored by the Nature aMPC16-CA50 Membranolytic Peptide Study and the Frontiers in Medicine 2026 Comprehensive Review

MDPI Antibiotics published a review paper synthesizing the dual antimicrobial-and-anticancer activity of frog-skin-derived peptides. The paper covers three main families: dermaseptins (originally isolated from Phyllomedusa frogs and studied since the 1990s), temporins (small linear peptides typically 10-14 amino acids from Rana temporaria and related species), and brevinins (larger amphipathic peptides from Rana and Sylvirana genera). Mechanism synthesis: the peptides disrupt microbial membranes through broad-spectrum cationic amphipathic activity against multidrug-resistant bacteria while also selectively targeting cancer cells through electrostatic interactions with the negatively charged phospholipid outer leaflets that are characteristic of many cancer cell membranes. Cancer-cell membrane disruption is followed by apoptosis or necrosis induction in ways that differ from traditional cytotoxic chemotherapy. The frog-skin AMP family represents one of the most-studied natural sources of bioactive antimicrobial peptides with cross-category therapeutic potential. The review extends the broader anticancer AMP research trajectory anchored by the August 7, 2026 Nature paper on the aMPC16-CA50 synthetic acid-responsive membranolytic peptide that induces immunogenic cell death and the Frontiers in Medicine 2026 comprehensive review on AMPs as cancer therapeutics and vaccine adjuvants. Clinical translation challenges remain (high toxicity at effective anticancer doses, poor systemic stability, limited cellular penetration, and costly synthesis) but the mechanism-of-action diversity across dermaseptins, temporins, and brevinins provides a broad pipeline for continued preclinical and early-clinical work.

#antimicrobial-peptide #amp #frog-skin-peptides #dermaseptins #temporins #brevinins #anticancer-peptide #membrane-disruption #mdpi-antibiotics #multidrug-resistant #immunogenic-cell-death #cross-category-amp